<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01608958</url>
  </required_header>
  <id_info>
    <org_study_id>3000</org_study_id>
    <nct_id>NCT01608958</nct_id>
  </id_info>
  <brief_title>IV vs IM Oxytocin in the Third Stage of Labor for Prevention of Postpartum Hemorrhage</brief_title>
  <official_title>Intravenous and Intramuscular Administration of Oxytocin in the Third Stage of Labor for Prevention of Postpartum Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynuity Health Projects</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Center for Research and Consultancy in Reproductive Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Huong Vuong Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>MOH Etlik Zubeyde Hanim Women's Health Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynuity Health Projects</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will evaluate whether prophylactic oxytocin administered in the third stage of
      labor via IV infusion results in a lower mean blood loss compared to IM injection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will compare the effect of IV infusion and IM oxytocin administration on the
      proportion of women who experience blood loss greater than or equal t 350 ml, the proportion
      of women who experience blood loss greater than or equal to 500 ml, side effects, adverse
      events and change in hemoglobin pre- to post-delivery. It will also assess whether a bleeding
      history questionnaire can identify women at risk for excessive bleeding and help to define
      the distribution of bleeding scores among women with and without excessive bleeding.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean blood loss (ml)</measure>
    <time_frame>minimum of 1 hour after delivery of baby</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of women who bleed greater or equal to 350 ml, 500 ml and 1000 ml</measure>
    <time_frame>minimum of 1 hour after delivery of baby</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin from pre-delivery to postpartum</measure>
    <time_frame>12-24 hours after delivery</time_frame>
    <description>Post-delivery hemoglobin using a Hemocue® Hemoglobin machine + cuvette will be taken at least 24 after delivery and before the woman leaves the facility. If the woman has received IV fluids, hemoglobin will be measured at least 12 hours after removal of the IV prior to discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to placental delivery</measure>
    <time_frame>minimum of 1 hour after delivery of baby</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Administration of additional oxytocin, other uterotonics, or other interventions such as blood transfusion and hysterectomy</measure>
    <time_frame>minimum of 1 hour after delivery of baby</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects 1 hour postpartum</measure>
    <time_frame>1 hour postpartum</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding scores calculated from a standardized questionnaire administered on arrival to labor ward</measure>
    <time_frame>arrival to labor ward</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">653</enrollment>
  <condition>Postpartum Hemorrhage</condition>
  <arm_group>
    <arm_group_label>IV infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxytocin 10 IU will be administered IV infusion according to randomization assignment as soon as possible after delivery of the baby.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IM Injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxytocin 10 IU will be administered IM according to randomization assignment as soon as possible after delivery of the baby.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>10 IU oxytocin in 500 ml infusion</description>
    <arm_group_label>IV infusion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>10 IU oxytocin IM injection</description>
    <arm_group_label>IM Injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All women who present in active labor for a live birth at the study hospital will be
             considered for participation in the study

        Exclusion Criteria: Women who are:

          -  Planned or transferred for delivery via Cesarean section

          -  Not delivering a live birth

          -  Unable to provide informed consent due to mental impairment, distress during labor or
             other reason

          -  Unwilling and/or unable to respond to questionnaires about background characteristics
             and/or bleeding history.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beverly Winikoff, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ilana Dzuba, MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jill Durocher</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jennifer Blum, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynuity Health Projects</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Gineco-Obstétrico Isidro Ayora</name>
      <address>
        <city>Quito</city>
        <country>Ecuador</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SB Etlik Zübeyde Hanım Kadın Hastalıkları Eğitim ve Araştırma Hastanesi</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huong Vuong Hospital</name>
      <address>
        <city>Ho Chi Minh City</city>
        <country>Vietnam</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ecuador</country>
    <country>Turkey</country>
    <country>Vietnam</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 29, 2012</study_first_submitted>
  <study_first_submitted_qc>May 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2012</study_first_posted>
  <last_update_submitted>March 25, 2016</last_update_submitted>
  <last_update_submitted_qc>March 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postpartum hemorrhage</keyword>
  <keyword>Oxytocin</keyword>
  <keyword>Third stage of labor</keyword>
  <keyword>Hemoglobin</keyword>
  <keyword>Prevention</keyword>
  <keyword>Intravenous</keyword>
  <keyword>Intramuscular</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Postpartum Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

